5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
- 2023-10
- RCT
- Journal of hepatology 79(4)
- Ranka Vukotic
- Roberto Di Donato
- Greta Roncarati
- Patrizia Simoni
- Matteo Renzulli
- Stefano Gitto
- Filippo Schepis
- Erica Villa
- Annalisa Berzigotti
- Jaume Bosch
- Pietro Andreone
- PubMed: 37482222
- DOI: 10.1016/j.jhep.2023.06.017
- High evidence
- Clinical
5-MTHF+propranolol (vs. placebo+propranolol) was associated with higher BH4 (1,101.4 ± 1,413.3 vs. 517.1 ± 242.8 pg/ml, p <0.001)
- Effect
- Beneficial
- Effect size
- Large
- Significant
- Yes